Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6708MR)

This product GTTS-WQ6708MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6708MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11112MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ13582MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ5222MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ1683MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ5155MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ1191MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ3604MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ550MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 4D5-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW